Medtronic Fights Investors' Appeal In Tainted Study Suit
Medtronic Inc. has urged the Eighth Circuit to affirm a decision dismissing a securities class action alleging the medical device maker manipulated studies for bone graft products to drive up share...To view the full article, register now.
Already a subscriber? Click here to view full article